Asia Pac IPO & Placement Research, China biotech, Aequitas Research

Ke Yan, CFA, FRM

An inquisitive investment analyst with background in both finance and computing. Covering ECM research, biotech, market data analytics.

Asia Pac IPO & Placement Research, China biotech

HK Short Interest Weekly: Galaxy Ent, Baba, East Buy, Anta Sports, Zijin Mining, Li Auto

HK Short Interest Weekly: Genscript Bio, CMB, Alibaba

HK Short Interest Weekly: Ganfeng Lithium, Picc P&C, Jd, Bidu, Manulife

HK Short Interest Weekly: Jd, Petrochina, Kingsoft, Link Reit, Bidu

HK Short Interest Weekly: Bidu, Baba, Byd Company

HK Short Interest Weekly: Meituan, Gcl Tech, Link Reit, Sensetime, Trip.Com, Hsbc, Baba, Wuxi Apptec

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Quantitative Analysis

China Consumer discretionary / Quantitative Analysis

<ul>
<li>We analyzed the latest HK SFC report for aggregate short position as of Apr 14th.</li>
<li>Top short increases and decreases were tabulated for one week and four week period. </li>
<li>We highlight short changes in Li Auto, Wuxi Bio, Baba, Tencent, Sensetime.</li>
</ul>


We analyzed the latest HK SFC report for aggregate short position as of Apr 14th.
Top short increases and decreases were tabulated for one week and four week period. 
We highlight short changes in Li Auto, Wuxi Bio, Baba, Tencent, Sensetime.


HK Short Interest Weekly: Li Auto, Wuxi Bio, Baba, Tencent, Sensetime

China Consumer Discretionary

HK Short Interest Weekly: Li Auto, Wuxi Bio, Baba, Tencent, Sensetime